Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations

被引:15
|
作者
Tamirat, Mahlet Z. [1 ]
Kurppa, Kari J. [2 ]
Elenius, Klaus [2 ,3 ,4 ,5 ]
Johnson, Mark S. [1 ]
机构
[1] Abo Akad Univ, Struct Bioinformat Lab, Biochem, Fac Sci & Engn, Turku 20520, Finland
[2] Univ Turku, Inst Biomed, MediC Res Labs, Turku 20520, Finland
[3] Turku Univ Hosp, Dept Oncol, Turku 20521, Finland
[4] Univ Turku, Turku Biosci Ctr, Turku 20520, Finland
[5] Abo Akad Univ, Turku 20520, Finland
基金
芬兰科学院;
关键词
EGFR tyrosine kinase; exon 20 insertion mutations; non-small cell lung cancer; molecular dynamics simulation; structural biology; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; KINASE DOMAIN; SOMATIC MUTATIONS; CLINICAL-RESPONSE; ERBB RECEPTORS; ACTIVATION; MECHANISM; INSIGHTS; ADENOCARCINOMAS;
D O I
10.3390/cancers13051120
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-small cell lung cancer (NSCLC) is the most common type of lung cancer that claims the lives of many worldwide. Activating mutations occurring on the epidermal growth factor receptor (EGFR) protein have been associated with the pathogenesis of NSCLC, among which exon 20 insertion mutations play a significant role. The objective of this study is to examine the dynamic structural changes occurring on the EGFR protein as a result of two common EGFR exon 20 insertion mutations, V769insASV and D770insNPG. The study further aims to uncover the mechanisms by which the insertion mutations increase kinase activity. Our results suggest that the insertion mutations stabilize structural elements key to maintaining the active EGFR conformation. Furthermore, the insertions disrupt an interaction essential in stabilizing the inactive conformation, which could drive the kinase from an inactive to an active EGFR state. Activating somatic mutations of the epidermal growth factor receptor (EGFR) are frequently implicated in non-small cell lung cancer (NSCLC). While L858R and exon 19 deletion mutations are most prevalent, exon 20 insertions are often observed in NSCLC. Here, we investigated the structural implications of two common EGFR exon 20 insertions in NSCLC, V769insASV and D770insNPG. The active and inactive conformations of wild-type, D770insNPG and V769insASV EGFRs were probed with molecular dynamics simulations to identify local and global alterations that the mutations exert on the EGFR kinase domain, highlighting mechanisms for increased enzymatic activity. In the active conformation, the mutations increase interactions that stabilize the alpha C helix that is essential for EGFR activity. Moreover, the key Lys745-Glu762 salt bridge was more conserved in the insertion mutations. The mutants also preserved the state of the structurally critical aspartate-phenylalanine-glycine (DFG)-motif and regulatory spine (R-spine), which were altered in wild-type EGFR. The insertions altered the structure near the ATP-binding pocket, e.g., the P-loop, which may be a factor for the clinically observed tyrosine kinase inhibitor (TKI) insensitivity by the insertion mutants. The inactive state simulations also showed that the insertions disrupt the Ala767-Arg776 interaction that is key for maintaining the "alpha C-out" inactive conformation, which could consequently fuel the transition from the inactive towards the active EGFR state.
引用
收藏
页码:1 / 21
页数:21
相关论文
共 50 条
  • [11] EGFR Exon 20 Insertion/Duplication Mutations Characterize Fibrous Hamartoma of Infancy
    Park, Jason Y.
    Cohen, Cynthia
    Lopez, Dania
    Ramos, Erica
    Wagenfuehr, Jennifer
    Rakheja, Dinesh
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (12) : 1713 - 1718
  • [12] Resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations
    Le, Xiuning
    Nilsson, Monique
    Chatterjee, Sampurna
    Su, Zhenqiang
    He, Junqin
    Udagawa, Hibiki
    Yu, Xiaoxing
    Poteete, Alissa
    Huang, Qian
    Heymach, John V.
    Vincent, Sylvie
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [13] Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
    Bazhenova, Lyudmila
    Minchom, Anna
    Viteri, Santiago
    Bauml, Joshua M.
    Ou, Sai-Hong Ignatius
    Gadgeel, Shirish M.
    Manuel Trigo, Jose
    Backenroth, Daniel
    Li, Tracy
    Londhe, Anil
    Mahadevia, Parthiv
    Girard, Nicolas
    LUNG CANCER, 2021, 162 : 154 - 161
  • [14] TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
    Hasako, Shinichi
    Terasaka, Miki
    Abe, Naomi
    Uno, Takao
    Ohsawa, Hirokazu
    Hashimoto, Akihiro
    Fujita, Ryoto
    Tanaka, Kenji
    Okayama, Takashige
    Wadhwa, Renu
    Miyadera, Kazutaka
    Aoyagi, Yoshimi
    Yonekura, Kazuhiko
    Matsuo, Kenichi
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (08) : 1648 - 1658
  • [15] Discovery of selective and potent EGFR kinase inhibitors for exon20 insertion mutations
    Kim, Sunghwan
    Lee, Younho
    Kim, Hwan
    Kang, Juhee
    Seok, Jiyoon
    Seo, Kyung-Ah
    Ahn, Jaeyoung
    Kang, Hee-Bum
    Lee, Sun-Hwa
    Son, Jung Beom
    Choi, Hwan Geun
    Kim, Nam Doo
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [16] Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations
    Mccoull, William
    Thomson, Clare
    Braybrooke, Erin
    Chan, Christina
    Colclough, Nicola
    Gonzalez, Miguel A. Cortes
    Cosulich, Sabina
    Davies, Nichola L.
    Floc'h, Nicolas
    Greenwood, Ryan
    Hargreaves, David
    Huang, Peng
    Hunt, Thomas A.
    Johnson, Tony
    Johnstrom, Peter
    Kettle, Jason G.
    Kondrashov, Mikhail
    Kostomiris, Demetrios H.
    Li, Songlei
    Lister, Andrew
    Martin, Scott
    Mckerrecher, Darren
    Mclean, Neville
    Nissink, J. Willem M.
    Orme, Jonathan P.
    Orwig, Paige
    Packer, Martin J.
    Pearson, Stuart
    Qin, Lina
    Felisberto-Rodrigues, Catarina
    Savoca, Adriana
    Schou, Magnus
    Stokes, Stephen
    Swaih, Aisha M.
    Talbot, Sara
    Tucker, Michael J.
    Ward, Richard A.
    Wadforth, Emma
    Wang, Chunli
    Wilson, Joanne
    Yang, Yawen
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 3700 - 3748
  • [17] Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
    Zhang, Shannon S.
    Zhu, Viola W.
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 61 - 65
  • [18] EGFR exon 20 insertion mutations in non-small cell lung cancer
    Wang, Fenfang
    Li, Chenghui
    Wu, Qihuan
    Lu, Hongyang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2982 - 2991
  • [19] Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
    Lv, D.
    Lin, L.
    Wu, X.
    Yan, S.
    Ge, H.
    Yan, Z.
    Wang, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S634 - S634
  • [20] Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
    Lin, Ling
    Wu, Xiaomai
    Yan, Shuangquan
    Zhu, Yefei
    Yan, Zhengqing
    Lv, Dongqing
    Ge, Hongfei
    ONCOTARGETS AND THERAPY, 2020, 13 : 9753 - 9757